Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Abhishek Paserkar։ Revolutionizing Hypertriglyceridemia Treatment With Olezarsen
Abhishek Paserkar/LinkedIn
Feb 3, 2026, 16:05

Abhishek Paserkar։ Revolutionizing Hypertriglyceridemia Treatment With Olezarsen

Abhishek Paserkar, Medical Doctor, shared a post on LinkedIn:

՛՛Revolutionizing Hypertriglyceridemia Treatment!

Excited to dive into this groundbreaking review on Olezarsen (Tryngolza) – the next-gen GalNAc-conjugated antisense oligonucleotide targeting ApoC-III for severe hypertriglyceridemia and Familial Chylomicronemia Syndrome (FCS)!

Published in Cureus (Nov 2025) by Joshy et al., it highlights how olezarsen slashes triglycerides by ~60% in FCS patients over 12 months, dramatically cutting pancreatitis events (just 1 vs. 11 on placebo in BALANCE trial)!

Key Highlights
Mechanism Magic: Inhibits hepatic ApoC-III, boosting LPL-dependent and independent triglyceride clearance – even in LPL-deficient FCS!

Trial Triumphs: Phase 3 BALANCE: TG decreased 59%, ESSENCE: decreased 58-61% in moderate HTG + CV risk. Ongoing CORE trials target pancreatitis prevention in severe HTG.

Safety Superstar: Mild injection-site reactions only; no thrombocytopenia like older volanesorsen. Monthly 80mg SC dose – convenient and tolerable!

This precision therapy (FDA-approved Dec 2024) transforms management of life-threatening TG disorders, paving the way for CV risk reduction. A must-read for pharmacologists, endocrinologists and lipid experts! ՛՛

Abhishek Paserkar։ Revolutionizing Hypertriglyceridemia Treatment With Olezarsen

Stay updated with Hemostasis Today.

 

Abhishek Paserkar Familial Chylomicronemia Syndrome Familial Chylomicronemia Syndrome (FCS) Health Hematology Hemostasis Hemostasis News Hemostasis Today Hypertriglyceridemia Medicine Olezarsen (Tryngolza)
NewsFeed